To ask the Secretary of State for Health, what plans the NHS has to use the drug T-Vec for the treatment of skin cancer.
10 June 2015
Talimogene laherparepvec (T-Vec) is still undergoing clinical trials and has not yet been licensed for the treatment of malignant melanoma by the regulatory authorities in either the United States or the European Union.
The Department has made no specfic assessment of research findings into its use to treat melanoma.
We take the issue of ensuring rapid access to innovative therapies very seriously, which is why we have launched an Accelerated Access Review to make recommendations to Government later in the year on speeding up access for National Health Service patients to innovative and cost effective new medicines, diagnostics and medical technologies.